MGX Stock Overview
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Metagenomi, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.53 |
| 52 Week High | US$12.74 |
| 52 Week Low | US$6.50 |
| Beta | 0 |
| 1 Month Change | -32.10% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| MGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.3% | -0.2% | 2.9% |
| 1Y | n/a | -1.0% | 22.2% |
Return vs Industry: Insufficient data to determine how MGX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MGX performed against the US Market.
Price Volatility
| MGX volatility | |
|---|---|
| MGX Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MGX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MGX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 236 | Brian Thomas | www.metagenomi.co |
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company’s genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
Metagenomi, Inc. Fundamentals Summary
| MGX fundamental statistics | |
|---|---|
| Market cap | US$282.17m |
| Earnings (TTM) | -US$68.25m |
| Revenue (TTM) | US$44.76m |
6.3x
P/S Ratio-4.1x
P/E RatioIs MGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGX income statement (TTM) | |
|---|---|
| Revenue | US$44.76m |
| Cost of Revenue | US$94.40m |
| Gross Profit | -US$49.65m |
| Other Expenses | US$18.61m |
| Earnings | -US$68.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | -110.93% |
| Net Profit Margin | -152.50% |
| Debt/Equity Ratio | 0% |
How did MGX perform over the long term?
See historical performance and comparison